{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T11:34:37Z","timestamp":1792236877147,"version":"4.4.0"},"reference-count":35,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2008,10,9]],"date-time":"2008-10-09T00:00:00Z","timestamp":1223510400000},"content-version":"vor","delay-in-days":2869,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2000,12]]},"abstract":"<jats:p> <jats:bold>\n            <jats:italic>Aims<\/jats:italic>\n          <\/jats:bold> To identify the human cytochrome P450 (CYP) isoforms mediating the <jats:italic>N<\/jats:italic>\u2010dealkylation of the antipsychotic drug perphenazine <jats:italic>in vitro<\/jats:italic> and estimate the relative contributions of the CYP isoforms involved.<\/jats:p><jats:p> <jats:bold>\n            <jats:italic>Methods<\/jats:italic>\n          <\/jats:bold> cDNA\u2010expressed CYP isoforms were used to identify the isoforms that are able to mediate the <jats:italic>N<\/jats:italic>\u2010dealkylation of perphenazine, which is considered a major metabolic pathway for the drug. Using human liver microsomal preparations (HLM), inhibition studies were carried out to establish the relative contributions of the CYP isoforms involved in the <jats:italic>N<\/jats:italic>\u2010dealkylation reaction.<\/jats:p><jats:p> <jats:bold>\n            <jats:italic>Results<\/jats:italic>\n          <\/jats:bold> CYP isoforms 1A2, 3A4, 2C8, 2C9, 2C18, 2C19 and 2D6 were able to mediate the <jats:italic>N<\/jats:italic>\u2010dealkylation of perphenazine. Reaction velocities and their relative abundance in HLM suggested that CYP1A2, 3A4, 2C19 and 2D6 were the most important contributors to <jats:italic>N<\/jats:italic>\u2010dealkylation. Apparent <jats:italic>K<\/jats:italic><jats:sub><jats:italic>m<\/jats:italic><\/jats:sub> values of CYP1A2 and CYP2D6 were in the range 1\u20132\u2003\u00b5<jats:sc>m<\/jats:sc>, and <jats:italic>K<\/jats:italic><jats:sub><jats:italic>m<\/jats:italic><\/jats:sub> values of CYP2C19 and CYP3A4 were 14\u2003\u00b5<jats:sc>m<\/jats:sc> and 7.9\u2003\u00b5<jats:sc>m<\/jats:sc>, respectively. Ketoconazole inhibition of <jats:italic>N<\/jats:italic>\u2010dealkylation mediated by a mixed HLM indicated that CYP3A4 accounted for about 40% of perphenazine <jats:italic>N<\/jats:italic>\u2010dealkylation at therapeutically relevant concentrations.The contribution of the CYP isoforms 1A2, 2C19 and 2D6 amounted to 20\u201325% each as measured by the percentage inhibition obtained by addition of furafylline, fluvoxamine or quinidine, respectively. HLM\u2010mediated <jats:italic>N<\/jats:italic>\u2010dealkylation of perphenazine accounted for 57% of the total amount of substrate consumed during incubation.<\/jats:p><jats:p> <jats:bold>\n            <jats:italic>Conclusions<\/jats:italic>\n          <\/jats:bold> The present <jats:italic>in vitro<\/jats:italic> study suggests that CYP isoforms 1A2, 3A4, 2C19 and 2CD6 are primarily involved in the <jats:italic>N<\/jats:italic>\u2010dealkylation of perphenazine. The relatively modest role of CYP2D6 is at variance with <jats:italic>in vivo<\/jats:italic> studies, which indicate a greater contribution of this isoform. Alternative metabolic pathways, corresponding to 43% of the HLM\u2010mediated metabolism of the drug, may depend more strongly on CYP2D6.<\/jats:p>","DOI":"10.1046\/j.1365-2125.2000.00298.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T04:40:29Z","timestamp":1047357629000},"page":"563-571","source":"Crossref","is-referenced-by-count":61,"title":["Identification of the human cytochrome P450 isoforms mediating <i>in vitro N<\/i>\u2010dealkylation of perphenazine"],"prefix":"10.1111","volume":"50","author":[{"given":"Ole V.","family":"Olesen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Linnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,10,9]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(74)90421-3"},{"key":"e_1_2_6_3_2","first-page":"437","article-title":"Tissue metabolites of trifluorperazine, fluphenazine, prochlorperazine, and perphenazine. Kinetics in chronic treatment","volume":"3","author":"Gaertner HJ","year":"1975","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1964.01720240093010"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00403866"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00432736"},{"key":"e_1_2_6_7_2","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2165\/00003088-198611010-00003","article-title":"Plasma level monitoring of antipsychotic drugs. Clinical utility","volume":"11","author":"Dahl SG","year":"1986","journal-title":"Clin Pharmacokin"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0278-5846(89)90013-4"},{"key":"e_1_2_6_9_2","first-page":"111","article-title":"Metabolism and pharmacokinetics of antipsychotic drugs","volume":"9","author":"Joergensen A","year":"1986","journal-title":"Prog Drug Metabolism"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(86)90793-4"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1979.tb00900.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1177\/00912709922008173"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00562943"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199708000-00013"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(97)90037-0"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1989.109"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(96)90165-4"},{"key":"e_1_2_6_18_2","first-page":"1379","article-title":"Metabolism of clozapine by cDNA\u2010expressed human cytochrome P450 enzymes","volume":"25","author":"Linnet K","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1990.tb03686.x"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050544"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.3109\/00498259509061850"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1998.00679.x"},{"key":"e_1_2_6_23_2","first-page":"154","article-title":"Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes","volume":"23","author":"Newton DJ","year":"1995","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_6_24_2","first-page":"321","article-title":"Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes","volume":"277","author":"Bourri\u00e9 M","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_6_25_2","first-page":"105","volume-title":"New York","author":"Segel IH","year":"1993"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1159\/000028333"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.116.3013.329"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1021\/js970435t"},{"key":"e_1_2_6_29_2","unstructured":"BaseltRC&CraveyRH.Disposition of toxic drugs and chemicals in man 4Chemical Toxicology Institute Foster City Ca 1995:598600."},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/23.2.127"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1976.tb00647.x"},{"key":"e_1_2_6_32_2","first-page":"1078","article-title":"Effect of antipsychotic drugs on human liver cytochrome P\u2010450 (CYP) isoforms in vitro: Preferential inhibition of CYP2D6","volume":"27","author":"Shin J\u2010G","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1986.tb02969.x"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1080\/004982500237541"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(96)90111-3"},{"key":"e_1_2_6_36_2","first-page":"414","article-title":"Interindividual variations in human liver cytochrome P\u2010450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and Caucasians","volume":"270","author":"Shimada T","year":"1994","journal-title":"J Pharmacol Exp Ther"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2125.2000.00298.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2125.2000.00298.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2125.2000.00298.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T09:28:40Z","timestamp":1698571720000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2125.2000.00298.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,12]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2000,12]]}},"alternative-id":["10.1046\/j.1365-2125.2000.00298.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2125.2000.00298.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,12]]}}}